Crispr Therapeutics Ag Stock Current Ratio
| 1CG Stock | 40.80 0.00 0.00% |
CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock.
CRISPR |
CRISPR Therapeutics AG Company Current Ratio Analysis
CRISPR Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, CRISPR Therapeutics AG has a Current Ratio of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Ratio (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
CRISPR Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CRISPR Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CRISPR Therapeutics could also be used in its relative valuation, which is a method of valuing CRISPR Therapeutics by comparing valuation metrics of similar companies.CRISPR Therapeutics is currently under evaluation in current ratio category among its peers.
CRISPR Fundamentals
| Current Valuation | 2.16 B | |||
| Price To Book | 6.67 X | |||
| Price To Sales | 1,731 X | |||
| Revenue | 436 K | |||
| EBITDA | (648.99 M) | |||
| Net Income | (650.17 M) | |||
| Cash Flow From Operations | (495.74 M) | |||
| Market Capitalization | 4.99 B | |||
| Total Asset | 2.24 B | |||
| Net Asset | 2.24 B |
About CRISPR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.